Mauna Kea Technologies (Paris, France) has received U.S. FDA clearance of its Cellvizio 100 series F400 and F800 confocal laser endomicroscopy (CLE) platforms with the company's CranioFlex confocal miniprobe to be used during neurosurgery.
The Cellvizio 100 with CranioFlex provides imaging of tissue internal microstructures, and allows identification of cells and vessels and their organization within the central nervous system during cranial diagnostic and therapeutic procedures such as tumor biopsy and resection. The Cellvizio 100 series F400 model operates at 488 nm and the F800 model at 800 nm, which are two highly relevant wavelengths commonly used during brain surgery for imaging and navigation.
The system paves the way toward more precise resection of brain and spinal tumors, says Sacha Loiseau, Ph.D., founder and CEO of Mauna Kea Technologies. It provides neurosurgeons the ability to perform real-time optical biopsies to help determine, for instance, if the tumor is completely excised.
For more information, please visit www.maunakeatech.com.